DXS InternationalSTU:7EE 39 PS Ratio is 0.17 as of Jul. 12, 2026, which is 82% below its 10-year median of 0.92. GuruFocus rates STU:7EE with a GF Score™ of 39/100 and a GF Value™ of €0.02. The stock has 2 warning signs investors should review. Among 659 Healthcare Providers & Services companies, DXS International ranks better than 91.65% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, DXS International's share price is €0.011.
DXS International's Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2025 was €0.06. Hence, DXS International's PS Ratio for today is 0.17.
The historical rank and industry rank for DXS International's PS Ratio or its related term are showing as below:
STU:7EE'
s PS Ratio Range Over the Past 10 Years
Min: 0.18 Med: 0.92 Max: 1.87
Current: 0.25
During the past 11 years, DXS International's highest PS Ratio was 1.87. The lowest was 0.18. And the median was 0.92.
STU:7EE's PS Ratio is ranked better than 91.65% of 659
companies
in the Healthcare Providers & Services industry
Industry Median: 1.48
vs STU:7EE: 0.25
DXS International PLC revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of DXS International was 3.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -10.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -6.20% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -3.70% per year.
During the past 11 years, DXS International's highest 3-Year average Revenue per Share Growth Rate was 12.90% per year. The lowest was -11.50% per year. And the median was -5.25% per year.
Back to Basics: PS Ratio
DXS International (STU:7EE) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
DXS International PS Ratio Related Terms
DXS International PS Ratio Historical Data
* Premium members only.
The historical data trend for DXS International's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, DXS International's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DXS International PS Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DXS International's PS Ratio distribution charts can be found below:
* The bar in red indicates where DXS International's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
DXS International's Share Price of today is €0.011.
For company reported annually, GuruFocus uses latest annual data as the TTM data. DXS International's Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2025 was €0.06.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
DXS International (STU:7EE) has a PS Ratio of 0.17 as of Jul. 12, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on DXS International and its competitors. This is 82% below median its historical median of 0.92. Over the past decade, DXS International's PS Ratio has ranged from 0.18 to 1.87. According to the industry distribution chart, DXS International ranks #55 out of 659 companies in the Healthcare Providers & Services industry, placing it in the top 8.3%.
Is DXS International's PS Ratio too high?
DXS International's current PS Ratio of 0.17 is 82% below median its 10-year median of 0.92. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 1.87. The Healthcare Providers & Services industry median PS Ratio is 1.48. DXS International's value of 0.17 is 88.5% below this industry median. Based on the distribution chart, DXS International ranks #55 out of 659 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, DXS International has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does DXS International's PS Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, DXS International ranks #55 out of 659 companies for PS Ratio. This places DXS International in the top 8% of its industry — outperforming the majority of peers. The industry median PS Ratio is 1.48. DXS International's value of 0.17 is 88.5% below this benchmark. Historically, DXS International's own PS Ratio has ranged from 0.18 to 1.87 over the past decade. While the company's 10-year median is 0.92 vs. the industry median of 1.48, DXS International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Healthcare Providers & Services company?
The median PS Ratio among Healthcare Providers & Services companies is 1.48, based on 659 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DXS International's current PS Ratio of 0.17 is 88.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on DXS International and its competitors. For the Healthcare Providers & Services industry, the median PS Ratio is 1.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DXS International's current PS Ratio is 0.17, which is 82% below median its own 10-year median of 0.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DXS International stock overvalued right now?
DXS International (STU:7EE) has a current PS Ratio of 0.17. The stock's GF Value™ is €0.02, compared to a current price of €0.01 — trading 45% below its estimated fair value. The current PS Ratio is 0.17, which is 82% below median its 10-year median of 0.92 and 88.5% below the Healthcare Providers & Services industry median of 1.48. DXS International's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For DXS International (STU:7EE), the current PS Ratio is 0.17 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DXS International (STU:7EE) Overvalued in 2026?
Based on GuruFocus' analysis, DXS International stock appears to be undervalued.
The current stock price of €0.01 is trading 45% below its estimated GF Value™ of €0.02.
Key valuation signals for STU:7EE:
PS Ratio: 0.17 (82% below median its 10-year median of 0.92)
GF Value™: €0.02 vs. price of €0.01 (45% below fair value)
Industry Position: 88.5% below the Healthcare Providers & Services median (#55 of 659)
No single metric tells the full story. See the STU:7EE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DXS International PLC is engaged in the development and distribution of clinical decision support systems for General Practitioners, nurses, and retail pharmacies in the United Kingdom and South Africa. Its commercial activities include licensing DXS products to various ICBs, offering e-detailing opportunities to the pharmaceutical industry and the UK primary care sector, and licensing its technology to healthcare publishers. The company's products include BestPathway and Point-of-Care ExpertCare.
39GF Score
Get the complete analysis for STU:7EE
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:7EE has been successfully added to your 
